Oral Rivaroxaban for Symptomatic Venous Thromboembolism
Open accessThe DOI matches its Crossref record, with a small difference in title or year; 20 of the 20 references it cites were found in a registry or an index.
Abstract
BACKGROUND: Rivaroxaban, an oral factor Xa inhibitor, may provide a simple, fixed-dose regimen for treating acute deep-vein thrombosis (DVT) and for continued treatment, without the need for laboratory monitoring. METHODS: We conducted an open-label, randomized, event-driven, noninferiority study that compared oral rivaroxaban alone (15 mg twice daily for 3 weeks, followed by 20 mg once daily) with subcutaneous enoxaparin followed by a vitamin K antagonist (either warfarin or acenocoumarol) for 3, 6, or 12 months in patients with acute, symptomatic DVT. In parallel, we carried out a double-blind, randomized, event-driven superiority study that compared rivaroxaban alone (20 mg once daily) with placebo for an additional 6 or 12 months in patients who had completed 6 to 12 months of treatment for venous thromboembolism. The primary efficacy outcome for both studies was recurrent venous thromboembolism. The principal safety outcome was major bleeding or clinically relevant nonmajor bleeding in the initial-treatment study and major bleeding in the continued-treatment study. RESULTS: The study of rivaroxaban for acute DVT included 3449 patients: 1731 given rivaroxaban and 1718 given enoxaparin plus a vitamin K antagonist. Rivaroxaban had noninferior efficacy with respect to the primary outcome (36 events [2.1%], vs. 51 events with enoxaparin-vitamin K antagonist [3.0%]; hazard ratio, 0.68; 95% confidence interval [CI], 0.44 to 1.04; P<0.001). The principal safety outcome occurred in 8.1% of the patients in each group. In the continued-treatment study, which included 602 patients in the rivaroxaban group and 594 in the placebo group, rivaroxaban had superior efficacy (8 events [1.3%], vs. 42 with placebo [7.1%]; hazard ratio, 0.18; 95% CI, 0.09 to 0.39; P<0.001). Four patients in the rivaroxaban group had nonfatal major bleeding (0.7%), versus none in the placebo group (P=0.11). CONCLUSIONS: Rivaroxaban offers a simple, single-drug approach to the short-term and continued treatment of venous thrombosis that may improve the benefit-to-risk profile of anticoagulation. (Funded by Bayer Schering Pharma and Ortho-McNeil; ClinicalTrials.gov numbers, NCT00440193 and NCT00439725.).
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“We conducted a subgroup analysis of the evidence of DOACs vs VKAs 86-97 and found no interaction between the specific agent used and the risk of mortality, PE, symptomatic DVT, or major bleeding.”
From American Society of Hematology 2020 guidelines for management of venous thromboembolism: treatment of deep vein thrombosis and pulmonary embolism (2020) · cites this paper as [88]
In the citing paper
“We conducted a subgroup analysis of the evidence of DOACs vs VKAs 86-97 and found no interaction between the specific agent used and the risk of mortality, PE, symptomatic DVT, or major bleeding.”
From American Society of Hematology 2020 guidelines for management of venous thromboembolism: treatment of deep vein thrombosis and pulmonary embolism (2020) · cites this paper as [88]
In the citing paper
“We conducted a subgroup analysis of the evidence of DOACs vs VKAs 86-97 and found no interaction between the specific agent used and the risk of mortality, PE, symptomatic DVT, or major bleeding.”
From American Society of Hematology 2020 guidelines for management of venous thromboembolism: treatment of deep vein thrombosis and pulmonary embolism (2020) · cites this paper as [88]
In the citing paper
“We conducted a subgroup analysis of the evidence of DOACs vs VKAs 86-97 and found no interaction between the specific agent used and the risk of mortality, PE, symptomatic DVT, or major bleeding.”
From American Society of Hematology 2020 guidelines for management of venous thromboembolism: treatment of deep vein thrombosis and pulmonary embolism (2020) · cites this paper as [88]
Citations
Cites
Dabigatran versus Warfarin in the Treatment of Acute Venous Thromboembolism
Schulman, S., Kearon, C., Kakkar, A. K., Mismetti, P., Schellong, S., Eriksson, H., Baanstra, D., Schnee, J., & Goldhaber, S. Z. (2009) · New England Journal of Medicine · doi:10.1056/nejmoa0906598 · Cited by 2,583
The Long-Term Clinical Course of Acute Deep Venous Thrombosis
Prandoni, P., Lensing, A. W. A., Cogo, A., Cuppini, S., Villalta, S., Carta, M., Cattelan, A. M., Polistena, P., Bernardi, E., & Prins, M. H. (1996) · Annals of Internal Medicine · doi:10.7326/0003-4819-125-1-199607010-00001 · Cited by 2,109
Antithrombotic Therapy for Venous Thromboembolic Disease
Kearon, C., Kahn, S. R., Agnelli, G., Goldhaber, S., Raskob, G. E., & Comerota, A. J. (2008) · Chest · doi:10.1378/chest.08-0658 · Cited by 1,996
Statistics in Medicine — Reporting of Subgroup Analyses in Clinical Trials
Wang, R., Lagakos, S. W., Ware, J. H., Hunter, D. J., & Drazen, J. M. (2007) · New England Journal of Medicine · doi:10.1056/nejmsr077003 · Cited by 1,445
Turpie, A. G., Lassen, M. R., Davidson, B. L., Bauer, K. A., Gent, M., Kwong, L. M., Cushner, F. D., Lotke, P. A., Berkowitz, S. D., Bandel, T. J., et al. (2009) · The Lancet · doi:10.1016/s0140-6736(09)60734-0 · Cited by 981
In-Stent Restenosis in the Drug-Eluting Stent Era
Dangas, G. D., Claessen, B. E., Caixeta, A., Sanidas, E. A., Mintz, G. S., & Mehran, R. (2010) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2010.07.028 · Cited by 803
Incidence of Venous Thromboembolism: A Community-based Study in Western France
Oger, E., & the EPI-GETBO Study Group (2000) · Thrombosis and Haemostasis · doi:10.1055/s-0037-1613887 · Cited by 711
KUBITZA, D., BECKA, M., VOITH, B., ZUEHLSDORF, M., & WENSING, G. (2005) · Clinical Pharmacology & Therapeutics · doi:10.1016/j.clpt.2005.06.011 · Cited by 649
Rodger, M. A., Kahn, S. R., Wells, P. S., Anderson, D. A., Chagnon, I., Le Gal, G., Solymoss, S., Crowther, M., Perrier, A., White, R., et al. (2008) · Canadian Medical Association Journal · doi:10.1503/cmaj.080493 · Cited by 581
Research works printed but not linked: 1
- Hutten BA, 2006, Cochrane Database Syst Rev, 1, CD001367
Cited by
Items 601–700 of 1,010
Apixaban: A novel oral inhibitor of factor Xa
Nutescu, E. A. (2012) · American Journal of Health-System Pharmacy · doi:10.2146/ajhp110418 · Cited by 39
Nonadherence with INR Monitoring and Anticoagulant Complications
Witt, D. M., Delate, T., Clark, N. P., Garcia, D. A., Hylek, E. M., Ageno, W., Dentali, F., & Crowther, M. A. (2013) · Thrombosis Research · doi:10.1016/j.thromres.2013.06.006 · Cited by 37
“To put this degree of increased risk in perspective, in clinical trials comparing dabigatran, rivaroxaban, and apixaban to warfarin for atrial fibrillation and venous thromboembolism, relative increases in thromboembolic risk ranging from 43% to 99% were considered non-inferior [15–19].”
BackgroundReiffel, J. A., Weitz, J. I., Reilly, P. A., Kaminskas, E., Sarich, T. C., Sager, P. T., & Seltzer, J. H. (2016) · American Heart Journal · doi:10.1016/j.ahj.2016.04.010 · Cited by 38
Key, N. S., Khorana, A. A., Mackman, N., McCarty, O. J. T., White, G., Francis, C. W., McCrae, K. R., Palumbo, J. S., Raskob, G. E., Chan, A. T., et al. (2016) · Cancer Research · doi:10.1158/0008-5472.can-15-3100 · Cited by 37
Influences of Obesity and Bariatric Surgery on the Clinical and Pharmacologic Profile of Rivaroxaban
Moore, K. T., & Kröll, D. (2017) · The American Journal of Medicine · doi:10.1016/j.amjmed.2017.05.011 · Cited by 38
Sun, M. T., Wood, M. K., Chan, W. O., Selva, D. N., Sanders, P., Casson, R. J., & Wong, C. X. J. (2017) · JAMA Ophthalmology · doi:10.1001/jamaophthalmol.2017.2199 · Cited by 46
Shaw, J. R., Woodfine, J. D., Douketis, J. D., Schulman, S., & Carrier, M. (2018) · Research and Practice in Thrombosis and Haemostasis · doi:10.1002/rth2.12076 · Cited by 39
The Role of Direct Oral Anticoagulants in Treatment of Cancer-Associated Thrombosis
Al-Samkari, H. T., & Connors, J. M. (2018) · Cancers · doi:10.3390/cancers10080271 · Cited by 41
“All patients in the SELECT-D trial and approximately 98% in the Hokusai VTE Cancer trial had active cancer at the time of enrollment, a major in contrast to the small number of patients classified as having cancer in the pivotal phase III randomized controlled VTE trials [33,35,36].”
ResultUse of Direct Oral Anticoagulants in Morbidly Obese Patients
Kido, K., Lee, J. C., Hellwig, T. R., & Gulseth, M. P. (2019) · Pharmacotherapy The Journal of Human Pharmacology and Drug Therapy · doi:10.1002/phar.2353 · Cited by 38
Wang, X., Ma, Y., Xu, H., Li, M., Li, J., Tian, J., Wang, Q., Yan, P., Li, J., Xie, P., et al. (2023) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd010956.pub3 · Cited by 52
Anticoagulation for prevention and treatment of cancer‐related venous thromboembolism
Barsam, S. J., Patel, R., & Arya, R. (2013) · British Journal of Haematology · doi:10.1111/bjh.12314 · Cited by 43
“%) between rivaroxaban and exoxaparin/vitamin K antagonist (Bauersachs et al, 2010; Siegal & Garcia, 2012).”
BackgroundПанченко, Е. П., Balahonova, T. V., Danilov, N. M., Komarov, A. L., Станиславовна, К. Е., Saidova, M. A., Shakhmatova, O. O., & Yavelov, I. S. (2021) · Eurasian heart journal · doi:10.38109/2225-1685-2021-1-44-77 · Cited by 39
Saraf, K., Morris, P., Garg, P., Sheridan, P. J., & Storey, R. F. (2014) · Postgraduate Medical Journal · doi:10.1136/postgradmedj-2014-132605 · Cited by 42
Treatment of established thrombotic events in patients with cancer
Lee, A. Y. Y. (2012) · Thrombosis Research · doi:10.1016/s0049-3848(12)70035-x · Cited by 39
“In the clinical trials evaluating VTE treatment, only about 5% of enrolled patients had cancer [25,43].”
BackgroundMethodHarenberg, J., Marx, S., Krämer, R., Giese, C., & Weiß, C. (2011) · Blood Coagulation & Fibrinolysis · doi:10.1097/mbc.0b013e328349f1d6 · Cited by 36
Hospitalization for vitamin-K-antagonist-related bleeding: treatment patterns and outcome
Halbritter, K., Beyer‐Westendorf, J., Nowotny, J., Pannach, S., Kuhlisch, E., & Schellong, S. (2013) · Journal of Thrombosis and Haemostasis · doi:10.1111/jth.12148 · Cited by 38
Recurrent venous thrombosis under rivaroxaban and carbamazepine for symptomatic epilepsy
Stöllberger, C., & Finsterer, J. (2017) · Neurologia i Neurochirurgia Polska · doi:10.1016/j.pjnns.2017.01.010 · Cited by 36
Anticoagulantes orales directos: puesta al día
Franco‐Moreno, A., Díaz, R. M. M., & Navarro, M. J. G. (2017) · Medicina Clínica · doi:10.1016/j.medcli.2017.11.042 · Cited by 39
Anticoagulation at the extremes of body weight: choices and dosing
McCaughan, G. J. B., Favaloro, E. J., Pasalic, L., & Curnow, J. L. (2018) · Expert Review of Hematology · doi:10.1080/17474086.2018.1517040 · Cited by 36
Recent Advances in the Management of Cancer-Associated Thrombosis: New Hopes but New Challenges
Frère, C., Benzidia, I., Marjanovic, Z., & Farge, D. (2019) · Cancers · doi:10.3390/cancers11010071 · Cited by 40
Principal Component Analysis on Recurrent Venous Thromboembolism
Martins, T. D., Annichino‐Bizzacchi, J. M., Romano, A. V. C., & Filho, R. M. (2019) · Clinical and Applied Thrombosis/Hemostasis · doi:10.1177/1076029619895323 · Cited by 39
Recommendations from the ICM-VTE: General
Delegates, T. I.-V. G. (2022) · Journal of Bone and Joint Surgery · doi:10.2106/jbjs.21.01531 · Cited by 38
Jennings, I., Kitchen, D. P., Keeling, D. M., Fitzmaurice, D. A., & Heneghan, C. J. (2014) · British Journal of Haematology · doi:10.1111/bjh.13070 · Cited by 36
“…with AF or venous thromboembolism (VTE) these new drugs are viable alternatives to warfarin (Connolly et al, 2009; Schulman et al, 2009, 2013; Bauersachs et al, 2010; Granger et al, 2011; Buller et al, 2012; Agnelli et al, 2013a,b; Giugliano et al, 2013; Hokusai-Investigators, 2013), and…”
BackgroundInherited and Secondary Thrombophilia
Cohoon, K. P., & Heit, J. A. (2014) · Circulation · doi:10.1161/circulationaha.113.001943 · Cited by 36
Du, W. D., Zhao, C., Wang, J., Liu, J., Shen, B.-H., & Zheng, Y. (2015) · Journal of Orthopaedic Surgery and Research · doi:10.1186/s13018-015-0223-7 · Cited by 36
“One study that used rivaroxaban as the routine anticoagulation therapy for 3449 cases of hip and knee replacement surgeries showed that rivaroxaban displayed similar anti-thrombotic efficacy to classic heparin but did not increase the risk of bleeding [7].”
BackgroundYamashita, Y., Morimoto, T., Amano, H., Takase, T., Hiramori, S., Kim, K., Oi, M., Akao, M., Kobayashi, Y., Toyofuku, M., et al. (2019) · Thrombosis Research · doi:10.1016/j.thromres.2019.02.029 · Cited by 36
Rivaroxaban and the EINSTEIN clinical trial programme
Cohen, A. T., & Bauersachs, R. M. (2019) · Blood Coagulation & Fibrinolysis · doi:10.1097/mbc.0000000000000800 · Cited by 43
New and Emerging Anticoagulant Therapy for Atrial Fibrillation and Acute Coronary Syndrome
Davis, E. M., Packard, K. A., Knezevich, J. T., & Campbell, J. A. (2011) · Pharmacotherapy The Journal of Human Pharmacology and Drug Therapy · doi:10.1592/phco.31.10.975 · Cited by 35
Therapy for Cancer-Related Thromboembolism
Frère, C., Debourdeau, P., Hij, A., Cajfinger, F., N'Guessan, M., Panicot‐Dubois, L., Dubois, C., & Farge, D. (2014) · Seminars in Oncology · doi:10.1053/j.seminoncol.2014.04.005 · Cited by 37
Cohen, A. T., Imfeld, S., & Rider, T. (2014) · Advances in Therapy · doi:10.1007/s12325-014-0119-7 · Cited by 40
“The placebo group of the EINSTEIN-Extension Table 4 continued EINSTEIN-Extension [21] AMPLIFY-Extension [20] RE-SONATE [24]”
BackgroundMethodResultInfluentialNovel oral anticoagulants in acute coronary syndrome
Costopoulos, C., Niespialowska-Steuden, M., Kukreja, N., & Gorog, D. A. (2012) · International Journal of Cardiology · doi:10.1016/j.ijcard.2012.08.014 · Cited by 35
Design of the rivaroxaban for heparin-induced thrombocytopenia study
Linkins, L., Warkentin, T. E., Pai, M., Shivakumar, S., Manji, R. A., Wells, P. S., & Crowther, M. A. (2014) · Journal of Thrombosis and Thrombolysis · doi:10.1007/s11239-014-1064-7 · Cited by 36
“The key advantages of using rivaroxaban for treatment of HIT include ease of administration, absence of a need for laboratory monitoring, lower cost and proven efficacy in the treatment of venous and arterial thromboembolism [10–13].”
BackgroundMethodCohen, A. T., Imfeld, S., Markham, J., & Granziera, S. (2014) · Thrombosis Research · doi:10.1016/j.thromres.2014.11.036 · Cited by 38
Who, when, and how to reverse non-vitamin K oral anticoagulants
Aronis, K. N., & Hylek, E. M. (2015) · Journal of Thrombosis and Thrombolysis · doi:10.1007/s11239-015-1297-0 · Cited by 39
“8 % respectively [2–4, 10–13].”
BackgroundInfluentialEscolar, G., Arellano‐Rodrigo, E., López-Vílchez, I., Molina, P., Sanchis, J., Reverter, J. C., Carné, X., Cid, J., Villalta, J., Tàssies, D., et al. (2014) · Circulation Journal · doi:10.1253/circj.cj-14-0909 · Cited by 35
Direct oral anticoagulants in hypercoagulable states
Kunk, P. R., Brown, J. T., McShane, M., Palkimas, S., & Macik, B. G. (2016) · Journal of Thrombosis and Thrombolysis · doi:10.1007/s11239-016-1420-x · Cited by 35
Bloemen, S., Zwaveling, S., Douxfils, J., Roest, M., Kremers, R., & Mullier, F. (2018) · Thrombosis Research · doi:10.1016/j.thromres.2018.10.005 · Cited by 35
Apixaban and rivaroxaban in patients with cerebral venous thrombosis
Covut, F., Kewan, T. Z., Perez, O., Flores, M., Haddad, A. S., & Daw, H. A. (2018) · Thrombosis Research · doi:10.1016/j.thromres.2018.11.018 · Cited by 35
Bradbury, C. A., Fletcher, K., Sun, Y., Heneghan, C. J., Gardiner, C., Roalfe, A. K., Hardy, P., McCahon, D., Heritage, G., Shackleford, H., et al. (2019) · British Journal of Haematology · doi:10.1111/bjh.16275 · Cited by 44
“…Campbell et al, 2007), two evaluated aspirin (Beccattini et al, 2012; Brighton et al, 2012) and four evaluated direct oral anticoagulants (DOACs) (Bauersachs et al, 2010; Romualdi et al, 2011; Agnelli et al, 2013; Schulman et al, 393 (40%, 393/993) pa ents fulfilled trial eligibility…”
Management of Outpatient Warfarin Therapy amid COVID-19 Pandemic: A Practical Guide
Kow, C. S., Sunter, W., Bain, A., Zaidi, S. T. R., & Hasan, S. S. (2020) · American Journal of Cardiovascular Drugs · doi:10.1007/s40256-020-00415-z · Cited by 37
Stroke Prevention in Atrial Fibrillation
Chiang, C., Chao, T., Choi, E., Lim, T. W., Krittayaphong, R., Li, M., Chen, M., Guo, Y., Okumura, K., & Lip, G. Y. H. (2022) · JACC Asia · doi:10.1016/j.jacasi.2022.05.005 · Cited by 37
“The dose of rivaroxaban undertaken in the ROCKET AF trial (20 mg once daily) was empirically chosen, based on its dose used in the EINSTEIN VTE trial, whereas the doses used in the RE-LY, ARISTOTLE, and ENGAGE-AF trials were supported by their individual phase II dose ranging trials.(4,37,38,48) There are major differ…”
MethodArachchillage, D. J., Efthymiou, M., Mackie, I. J., Lawrie, A. S., Machin, S. J., & Cohen, H. (2014) · Thrombosis Research · doi:10.1016/j.thromres.2014.11.037 · Cited by 35
“Clinical outcome measures in patients receiving warfarin or rivaroxaban have been assessed in a number of different multicentre prospective clinical trials involving many thousands of patients, including those with VTE [13–15].”
BackgroundKabrhel, C., Rosovsky, R. P. G., Baugh, C. W., Connors, J. M., White, B. A., Giordano, N. J., Torrey, J., Deadmon, E. K., Parry, B. A., Hagan, S. C., et al. (2018) · Academic Emergency Medicine · doi:10.1111/acem.13640 · Cited by 35
Robertson, L., Yeoh, S. E., Stansby, G. P., & Agarwal, R. (2015) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd010837.pub2 · Cited by 35
Diagnosis and Management of Pulmonary Embolism
Trott, T., & Bowman, J. (2022) · Emergency Medicine Clinics of North America · doi:10.1016/j.emc.2022.05.008 · Cited by 48
Oral Anticoagulation and Risk of Adverse Clinical Outcomes in Venous Thromboembolism
Bea, S., Iyer, G. S., Kim, D., Lin, K. J., Zhang, Y., Zakoul, H., Tesfaye, H., & Bykov, K. (2025) · JAMA Internal Medicine · doi:10.1001/jamainternmed.2025.1109 · Cited by 39
Management of venous thromboembolism in cancer patients and the role of the new oral anticoagulants
Wharin, C., & Tagalakis, V. (2013) · Blood Reviews · doi:10.1016/j.blre.2013.11.001 · Cited by 36
Tellor, K. B., Patel, S. I., Armbruster, A. L., & Daly, M. W. (2015) · Journal of Clinical Pharmacy and Therapeutics · doi:10.1111/jcpt.12288 · Cited by 36
Non-vitamin K antagonist oral anticoagulants and antiphospholipid syndrome
Sciascia, S., López-Pedrera, C., Cecchi, I., Pecoraro, C., Roccatello, D., & Cuadrado, M. J. (2016) · Rheumatology · doi:10.1093/rheumatology/kev445 · Cited by 36
Long-term Anticoagulation With Rivaroxaban for Preventing Recurrent VTE
Wells, P. S., Prins, M. H., Levitan, B. S., Beyer‐Westendorf, J., Brighton, T., Bounameaux, H., Cohen, A. T., Davidson, B. L., Prandoni, P., Raskob, G. E., et al. (2016) · CHEST Journal · doi:10.1016/j.chest.2016.05.023 · Cited by 40
Direct oral anticoagulants and venous thromboembolism
Franchini, M., & Mannucci, P. M. (2016) · European Respiratory Review · doi:10.1183/16000617.0025-2016 · Cited by 40
Lullo, L. D., Ronco, C., Cozzolino, M. G., Russo, D., Russo, L., Iorio, B. R. D., Pascalis, A. D., Bàrbera, V., Galliani, M., Vitaliano, E., et al. (2017) · Thrombosis Research · doi:10.1016/j.thromres.2017.04.027 · Cited by 34
Wood, B., Nascimento, B., Rizoli, S. B., Sholzberg, M., McFarlan, A., Phillips, A., & Ackery, A. (2017) · Scandinavian Journal of Trauma Resuscitation and Emergency Medicine · doi:10.1186/s13049-017-0420-y · Cited by 34
The Non-Vitamin K Antagonist Oral Anticoagulants in Heart Disease: Section V—Special Situations
Caterina, R. D., Ageno, W., Agnelli, G., Chan, N., Diener, H., Hylek, E. M., Raskob, G. E., Siegal, D. M., Verheugt, F. W. A., Lip, G. Y. H., et al. (2018) · Thrombosis and Haemostasis · doi:10.1055/s-0038-1675816 · Cited by 37
Venous thromboembolism: A clinician update
Serhal, M., & Barnes, G. D. (2019) · Vascular Medicine · doi:10.1177/1358863x18821159 · Cited by 37
Extended Anticoagulation for VTE
Mai, V., Guay, C.-A., Perreault, L., Bonnet, S., Bertoletti, L., Lacasse, Y., Mainbourg, S., Lega, J., & Provencher, S. (2019) · CHEST Journal · doi:10.1016/j.chest.2019.02.402 · Cited by 38
Comparative effectiveness of oral anticoagulants in venous thromboembolism: GARFIELD-VTE
Bounameaux, H., Haas, S. K., Farjat, A. E., Ageno, W., Weitz, J. I., Goldhaber, S. Z., Turpie, A. G. G., Goto, S., Angchaisuksiri, P., Nielsen, J. D., et al. (2020) · Thrombosis Research · doi:10.1016/j.thromres.2020.04.036 · Cited by 35
A review of upper extremity deep vein thrombosis
Khan, O., Marmaro, A., & Cohen, D. A. (2021) · Postgraduate Medicine · doi:10.1080/00325481.2021.1892390 · Cited by 38
Long-term clinical course of acute pulmonary embolism
den Exter, P. L., van der Hulle, T., Lankeit, M., Huisman, M. V., & Klok, F. A. (2013) · Blood Reviews · doi:10.1016/j.blre.2013.06.003 · Cited by 42
“In the EINSTEIN-EXT trial, VTE patients were randomized to the direct factor Xa inhibitor rivaroxaban 20 mg once daily versus placebo for a period of six to twelve months after successfully completed initial treatment for six to twelve months [61].”
MethodHillis, C., & Crowther, M. A. (2015) · Thrombosis and Haemostasis · doi:10.1160/th14-12-1036 · Cited by 36
Venous Thromboembolism in Heart Failure Patients
Goldhaber, S. Z. (2020) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2019.11.028 · Cited by 34
Lee, F. M. H., Chan, A. K. C., Lau, K. K., & Chan, H. H. W. (2014) · Thrombosis Research · doi:10.1016/j.thromres.2014.01.031 · Cited by 33
New anticoagulants for treatment of venous thromboembolism
Franchini, M., & Mannucci, P. M. (2012) · European Journal of Internal Medicine · doi:10.1016/j.ejim.2012.10.001 · Cited by 36
“The EINSTEIN extension study [19] chose to evaluate whether or not extended duration of rivaroxaban administration (6–12 months) in patients who had previously completed 6–12 months of therapy in the EINSTEINDVT study is superior to placebowith respect to the rate of recurrent VTE.”
BackgroundMethodResultInfluentialBlutungsrisiko und Blutungsnotfälle unter Rivaroxaban: Periinterventionelles Hämostase management
Koscielny, J., Beyer‐Westendorf, J., von Heymann, C., Braun, J., Klamroth, R., Lindhoff‐Last, E., Tiede, A., & Spannagl, M. (2012) · Hämostaseologie · doi:10.5482/ha-2012030001 · Cited by 33
Novel Oral Anticoagulants: Efficacy, Laboratory Measurement, and Approaches to Emergent Reversal
Gehrie, E. A., & Tormey, C. A. (2015) · Archives of Pathology & Laboratory Medicine · doi:10.5858/arpa.2013-0677-rs · Cited by 33
Cancer-associated thrombosis: investigating the role of new oral anticoagulants
Franchini, M., Bonfanti, C., & Lippi, G. (2015) · Thrombosis Research · doi:10.1016/j.thromres.2015.02.024 · Cited by 38
Tornyos, A., Kehl, D., D’Ascenzo, F., & Komócsi, A. (2015) · Progress in Cardiovascular Diseases · doi:10.1016/j.pcad.2015.12.001 · Cited by 36
Efficacy and safety of novel anticoagulants in the elderly.
Karamichalakis, N., Georgopoulos, S., Vlachos, K. G., Liatakis, I., Efremidis, M., Sideris, A., & Letsas, Κ. P. (2016) · PubMed Central · doi:10.11909/j.issn.1671-5411.2016.08.011 · Cited by 39
Rivaroxaban in the Treatment of PICC-associated Upper Extremity Venous Thrombosis
Fan, F., Zou, Y., Zhang, S., Zhang, Y., Lan, B., Song, Q., Pei, M., He, L., Wu, H., Du, Y., et al. (2017) · Clinical Therapeutics · doi:10.1016/j.clinthera.2017.07.041 · Cited by 35
Mai, V., Bertoletti, L., Cucherat, M., Mainbourg, S., Grangé, C., Provencher, S., & Lega, J. (2019) · PLoS ONE · doi:10.1371/journal.pone.0214134 · Cited by 35
McBane, R. D., Loprinzi, C. L., Ashrani, A. A., Lenz, C. J., Houghton, D. E., Zemla, T., Le‐Rademacher, J. G., & Wysokiński, W. E. (2019) · European Journal Of Haematology · doi:10.1111/ejh.13338 · Cited by 33
Adedeji, A., Chukwura, O., Obafemi, T., McNulty, S. B., & Reinert, J. P. (2020) · Annals of Pharmacotherapy · doi:10.1177/1060028020957620 · Cited by 36
Use of oral rivaroxaban in cerebral venous thrombosis
Maqsood, M. Z., Khan, M. I., Yameen, M., Ahmed, K. A., Hussain, N., & Hussain, S. (2020) · Journal of Drug Assessment · doi:10.1080/21556660.2020.1838769 · Cited by 33
Advanced micro/nanomotors for enhanced bioadhesion and tissue penetration
Lv, J., Xing, Y., Xu, T., Zhang, X., & Du, X. C. (2021) · Applied Materials Today · doi:10.1016/j.apmt.2021.101034 · Cited by 35
Genge, L., Krala, A., Tritschler, T., Gal, G. L., Langlois, N., Dubois, S., West, C., Duffett, L. D., & Skeith, L. (2022) · Journal of Thrombosis and Haemostasis · doi:10.1111/jth.15788 · Cited by 37
The discovery and development of rivaroxaban
Misselwitz, F., Berkowitz, S. D., & Perzborn, E. (2011) · Annals of the New York Academy of Sciences · doi:10.1111/j.1749-6632.2011.05971.x · Cited by 34
Goldenberg, N. A., Takemoto, C. M., Yee, D. L., Kittelson, J. M., & Massicotte, M. P. (2015) · Blood · doi:10.1182/blood-2015-06-651539 · Cited by 33
Venous thromboembolism: Predicting recurrence and the need for extended anticoagulation
Barnes, G. D., Kanthi, Y. M., & Froehlich, J. B. (2015) · Vascular Medicine · doi:10.1177/1358863x14566429 · Cited by 40
Rivaroxaban for the treatment of consumptive coagulopathy associated with a vascular malformation
Vandenbriele, C., Vanassche, T., Peetermans, M., Verhamme, P. B., & Peerlinck, K. (2013) · Journal of Thrombosis and Thrombolysis · doi:10.1007/s11239-013-1024-7 · Cited by 35
“Because the main anticoagulant effect of LMWHs is based on factor Xa inhibition, we opted for the oral factor Xa inhibitor rivaroxaban, recently been approved for the prevention of thromboembolic complications in atrial fibrillation [13], for the prevention of venous thromboembolism (VTE) after major orthopaedic surge…”
BackgroundOh, H. J., Ryu, K. H., Park, B. J., & Yoon, B. (2021) · Medicine · doi:10.1097/md.0000000000025216 · Cited by 34
“However, a few studies (the EINSTEIN acute deep vein thrombosis, the EINSTEIN-PE and the RE-LY study) [7,30,47] were open-label RCTs, and consequently allocation concealment procedures and blinding of participants and study personnel items were considered to be of high risk of bias (Supplemental Fig.”
Haładyj, E., & Olesińska, M. (2016) · Reumatologia/Rheumatology · doi:10.5114/reum.2016.61217 · Cited by 32
Pathogenesis, Diagnosis, and Treatment of Venous Thromboembolism in Older Adults
Johnson, S. A., Eleazer, G. P., & Rondina, M. T. (2016) · Journal of the American Geriatrics Society · doi:10.1111/jgs.14279 · Cited by 35
Rigano, J., Ng, C., Nandurkar, H. H., & Ho, P. W. (2017) · Blood Coagulation & Fibrinolysis · doi:10.1097/mbc.0000000000000678 · Cited by 36
Wille, K., Sadjadian, P., Becker, T. M., Kolatzki, V., Horstmann, A., Fuchs, C., & Grießhammer, M. (2018) · Annals of Hematology · doi:10.1007/s00277-018-3483-6 · Cited by 34
Current status of oral anticoagulant reversal strategies: a review
Rawal, A., Ardeshna, D. R., Minhas, S., Cave, B. E., Ibeguogu, U., & Khouzam, R. N. (2019) · Annals of Translational Medicine · doi:10.21037/atm.2019.07.101 · Cited by 32
Direct Anticoagulants and Risk of Myocardial Infarction, a Multiple Treatment Network Meta-Analysis
Kupó, P., Szakács, Z., Solymár, M., Habon, T., Czopf, L., Haţegan, L., Csányi, B., Borbás, J., Tringer, A., Varga, G., et al. (2019) · Angiology · doi:10.1177/0003319719874255 · Cited by 35
Severe renal impairment and risk of bleeding during anticoagulation for venous thromboembolism
Catella, J., Bertoletti, L., Mismetti, P., Ollier, É., Samperiz, A. L., Soler, S., Suriñach, J. M., Mahé, I., Lorente, M. A., Braester, A., et al. (2020) · Journal of Thrombosis and Haemostasis · doi:10.1111/jth.14837 · Cited by 34
Wu, C. M., Alotaibi, G., AlSaleh, K. A., & McMurtry, M. S. (2014) · Thrombosis Research · doi:10.1016/j.thromres.2014.07.001 · Cited by 34
“Clinical trials have shown each of these agents to be at least as effective and safe as VKAs for the acute treatment of VTE and the secondary prevention of recurrent VTE [9–15].”
BackgroundMethodContemporary management of acute and chronic deep venous thrombosis
Saha, P., Black, S. A., Breen, K. A., Patel, A. S., Modarai, B., & Smith, A. (2016) · British Medical Bulletin · doi:10.1093/bmb/ldw006 · Cited by 37
Mukdad, M. A., Al‐Badriyeh, D., & Elewa, H. F. (2019) · Clinical and Applied Thrombosis/Hemostasis · doi:10.1177/1076029619849103 · Cited by 34
Safety of direct oral anticoagulants versus traditional anticoagulants in venous thromboembolism
Giustozzi, M., Franco, L., Vedovati, M. C., Becattini, C., & Agnelli, G. (2019) · Journal of Thrombosis and Thrombolysis · doi:10.1007/s11239-019-01878-x · Cited by 38
Soff, G. A., Mones, J. V., Wilkins, C. R., Devlin, S. M., Haegler‐Laube, E., Wills, J., Sarasohn, D. M. M., Juluru, K., Singer, M., Miao, Y., et al. (2019) · Research and Practice in Thrombosis and Haemostasis · doi:10.1002/rth2.12215 · Cited by 32
Reversal of New Oral Anticoagulants
Battinelli, E. M. (2011) · Circulation · doi:10.1161/circulationaha.111.054510 · Cited by 32
Thromboembolism in Older Adults
Gross, P. L., & Chan, N. (2021) · Frontiers in Medicine · doi:10.3389/fmed.2020.470016 · Cited by 36
Stevenson, J. W., Minns, A. B., Smollin, C. G., Albertson, T. E., Cantrell, F. L., Tomaszewski, C., & Clark, R. F. (2014) · The American Journal of Emergency Medicine · doi:10.1016/j.ajem.2014.04.031 · Cited by 32
Practical issues, limitations, and periprocedural management of the NOAC’s
Connolly, G. C., & Spyropoulos, A. C. (2013) · Journal of Thrombosis and Thrombolysis · doi:10.1007/s11239-013-0911-2 · Cited by 31
Moving Toward a More Ideal Anticoagulant
King, C. S., Holley, A. B., & Moores, L. K. (2013) · CHEST Journal · doi:10.1378/chest.12-1362 · Cited by 32
New Oral Anticoagulants in Patients With Cancer: Current State of Evidence
Sardar, P., Chatterjee, S., Herzog, E., Pekler, G., Mushiyev, S., Pastori, L. J., Visco, F., & Aronow, W. S. (2014) · American Journal of Therapeutics · doi:10.1097/mjt.0000000000000055 · Cited by 34
Amin, A., Bruno, A. S., Trocio, J. N., Lin, J., & Lingohr-Smith, M. (2015) · Journal of Medical Economics · doi:10.3111/13696998.2015.1007210 · Cited by 37
Armbruster, A. L., Buehler, K. S., Min, S. H., Riley, M., & Daly, M. W. (2014) · American health & drug benefits · Cited by 38
Metadata
- Authors
- The EINSTEIN Investigators
- Corresponding author
- The EINSTEIN Investigators
- Venue
- New England Journal of Medicine
- Publisher
- Massachusetts Medical Society
- Published
- 2010-12-23
- Volume
- 363
- Issue
- 26
- Pages
- 2499-2510
- ISSN
- 0028-4793 (ISSN-L)
- 1533-4406
- OpenAlex
- W2115787552
- Cited by
- 3,237
- References
- 19
- Citations by year
- 2026: 90 · 2025: 105 · 2024: 118 · 2023: 153 · 2022: 169 · 2021: 189 · 2020: 261 · 2019: 242 · 2018: 248 · 2017: 232 · 2016: 300 · 2015: 267 · 2014: 290 · 2013: 255 · 2012: 188
- FWCI
- 148.86
- Type
- journal article
- Language
- en
- Open access
- bronze
- doi.org
- Locations
- New England Journal of Medicine (publishedVersion)
- PubMed (publishedVersion)
- Research Publications (Maastricht University) (publishedVersion, other-oa)
- Pure Amsterdam UMC (publishedVersion)
- ORBi (University of Liège) (acceptedVersion, other-oa)
- Murdoch University Research Portal (submittedVersion)
- Data Archiving and Networked Services (DANS) (submittedVersion)
- HAL (submittedVersion)
- Universitätsbibliographie, Universität Duisburg-Essen (submittedVersion)
- DIAL (Catholic University of Leuven) (submittedVersion)
- Flinders Academic Commons (Flinders University) (submittedVersion)
- UCL Discovery (University College London) (submittedVersion)
- IrInSubria (University of Insubria) (submittedVersion)
- IRIS (submittedVersion)
- SERVAL (Université de Lausanne) (submittedVersion)
- Archive ouverte UNIGE (University of Geneva) (submittedVersion)
- Archive ouverte UNIGE (University of Geneva) (submittedVersion, cc-by)
- Research Publications (Maastricht University) (submittedVersion)
- Topics
- Health Sciences › Medicine › Internal Medicine › Venous Thromboembolism Diagnosis and Management
- Health Sciences › Medicine › Hematology › Blood Coagulation and Thrombosis Mechanisms
- Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Atrial Fibrillation Management and Outcomes
- Keywords
- rivaroxaban, oral factor Xa inhibitors, venous thromboembolism, deep vein thrombosis, continuation treatment, recurrent venous thromboembolism, enoxaparin, vitamin K antagonists, warfarin, acenocoumarol, major bleeding, non-inferiority
- MeSH terms
- Rivaroxaban, Acenocoumarol, Acute Disease, Administration, Oral, Aged, Anticoagulants, Double-Blind Method, Female, Hemorrhage, Humans, Injections, Subcutaneous, Male, Middle Aged, Morpholines, Pulmonary Embolism, Thiophenes, Vitamin K, Warfarin, Enoxaparin, Venous Thrombosis, Kaplan-Meier Estimate, Venous Thromboembolism, Intention to Treat Analysis, Factor Xa Inhibitors
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.